CIK: 0001822947
Total reported value
$123.8M
Reporting period: 2026-03-31 · Number of holdings: 28
Ally Bridge Group (NY) LLC disclosed 28 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $123.8M and a quarterly turnover rate of 95.1%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "A"
Sector classification currently covers about 0% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim REPL
-79.4% -$9.8M
Trim EWTX
-63.8% -$6.0M
Trim ABVX
-51.8% -$5.7M
Trim IVA
-50.3% -$2.8M
Trim CMPS
-5.0% -$1.8M
Add SLNOEUR
+138.1% $5.6M
Showing top 26 holdings (of 28 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SLNOEUR | Soleno Therapeutics INC | Stock-Other | 10.82% | +2.72% | +138.05% | |
| 2 | PRAX | Praxis Precision Medicines I | Stock-Other | 8.54% | +2.44% | +65.02% | |
| 3 | NERV | Minerva Neurosciences INC | Stock-Other | 8.06% | +1.13% | — | |
| 4 | OVID | Ovid Therapeutics INC | Stock-Other | 5.05% | +2.02% | +57.90% | |
| 5 | CMPS | Compass Pathways PLC | Stock-Other | 4.67% | -3.24% | -5.00% | |
| 6 | TARS | Tarsus Pharmaceuticals INC | Stock-Other | 4.58% | +4.58% | NEW | |
| 7 | SLDB | Solid Biosciences INC | Stock-Other | 4.46% | +2.03% | +85.43% | |
| 8 | CMPX | Compass Therapeutics INC | Stock-Other | 4.27% | +4.27% | NEW | |
| 9 | PMN | Promis Neurosciences INC | Stock-Other | 4.25% | +2.48% | +66.13% | |
| 10 | EWTX | Edgewise Therapeutics INC | Stock-Other | 4.10% | -7.40% | -63.82% | |
| 11 | QURE | uniQure N.V. | Stock-Other | 3.96% | -1.03% | +50.00% | |
| 12 | EPRX | Eupraxia Pharmaceuticals INC | Stock-Other | 3.86% | +0.73% | +65.97% | |
| 13 | CTMX | Cytomx Therapeutics INC | Stock-Other | 3.42% | +3.42% | NEW | |
| 14 | IVA | Inventiva SA - Adr | Stock-Other | 3.34% | -3.93% | -50.31% | |
| 15 | CATX | Perspective Therapeutics INC | Stock-Other | 3.12% | +3.12% | NEW | |
| 16 | ABVX | Abivax Sa-adr | Stock-Other | 3.03% | -6.80% | -51.84% | |
| 17 | ALMS | Alumis INC | Stock-Other | 2.97% | +2.97% | NEW | |
| 18 | URGN | UroGen Pharma Ltd. | Stock-Other | 2.94% | +2.94% | NEW | |
| 19 | CAPR | Capricor Therapeutics INC | Stock-Other | 2.80% | +2.80% | NEW | |
| 20 | MAZE | Maze Therapeutics INC | Stock-Other | 2.41% | +2.41% | NEW | |
| 21 | WHWK | Whitehawk Therapeutics INC | Stock-Other | 2.28% | +0.22% | — | |
| 22 | IKT | Inhibikase Therapeutics INC | Stock-Other | 1.80% | +1.80% | NEW | |
| 23 | REPL | Replimune Group INC | Stock-Other | 1.53% | -10.62% | -79.42% | |
| 24 | ANTX | An2 Therapeutics INC | Stock-Other | 1.45% | +1.45% | NEW | |
| 25 | RLMD | Relmada Therapeutics INC | Stock-Other | 1.18% | +1.18% | NEW | |
| 26 | KPTI | Karyopharm Therapeutics INC | Stock-Other | 1.12% | +1.12% | NEW |
Performance for Q3 2026
+21.2%
Performance Last 4 Quarters
+14.5%
Based on 77% of reported portfolio value with available pricing
Not enough sector-mapped data yet
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 28 | $123.8M | 95 | |
| 2025-12-31 | 20 | $96.0M | 100 | |
| 2025-09-30 | 25 | $164.2M | 100 | |
| 2025-06-30 | 24 | $120.2M | 0 | |
| 2025-03-31 | 28 | $110.9M | 100 | |
| 2024-12-31 | 30 | $116.6M | 0 | |
| 2024-09-30 | 29 | $186.8M | 0 | |
| 2024-06-30 | 25 | $167.9M | 0 | |
| 2024-03-31 | 22 | $179.9M | 0 | |
| 2023-12-31 | 22 | $167.8M | 0 | |
| 2023-09-30 | 19 | $85.2M | 0 | |
| 2023-06-30 | 17 | $82.6M | 0 | |
| 2023-03-31 | 18 | $76.3M | 0 | |
| 2022-12-31 | 30 | $102.8M | 0 | |
| 2022-09-30 | 39 | $151.5M | 0 | |
| 2022-06-30 | 22 | $109.7M | 0 | |
| 2022-03-31 | 21 | $134.9M | 0 | |
| 2021-12-31 | 30 | $286.1M | 0 | |
| 2021-09-30 | 31 | $340.1M | 0 | |
| 2021-06-30 | 29 | $402.5M | 100 | |
| 2021-03-31 | 32 | $521.6M | 50 | |
| 2020-12-31 | 30 | $583.5M | 0 |
Ally Bridge Group (NY) LLC's most significant position changes for 2026-03-31: Sold out: AtaiBeckley Inc. (ATAI); New buy: Tarsus Pharmaceuticals INC (TARS); New buy: Compass Therapeutics INC (CMPX); Sold out: Taysha Gene Therapies INC (TSHA); New buy: Cytomx Therapeutics INC (CTMX).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SLNOEUR | Soleno Therapeutics INC | +2.7% | +138.05% | Add |
| 2 | PMN | Promis Neurosciences INC | +2.5% | +66.13% | Add |
| 3 | PRAX | Praxis Precision Medicines I | +2.4% | +65.02% | Add |
| 4 | SLDB | Solid Biosciences INC | +2% | +85.43% | Add |
| 5 | OVID | Ovid Therapeutics INC | +2% | +57.90% | Add |
| 6 | NERV | Minerva Neurosciences INC | +1.1% | — | Unchanged |
| 7 | EPRX | Eupraxia Pharmaceuticals INC | +0.7% | +65.97% | Add |
| 8 | WHWK | Whitehawk Therapeutics INC | +0.2% | — | Unchanged |
| 9 | QURE | uniQure N.V. | -1% | +50.00% | Add |
| 10 | CMPS | Compass Pathways PLC | -3.2% | -5.00% | Trim |
| 11 | IVA | Inventiva SA - Adr | -3.9% | -50.31% | Trim |
| 12 | ABVX | Abivax Sa-adr | -6.8% | -51.84% | Trim |
| 13 | EWTX | Edgewise Therapeutics INC | -7.4% | -63.82% | Trim |
| 14 | REPL | Replimune Group INC | -10.6% | -79.42% | Trim |
| 15 | ATAI | AtaiBeckley Inc. | — | EXIT | Sold out |
| 16 | TARS | Tarsus Pharmaceuticals INC | — | NEW | New buy |
| 17 | CMPX | Compass Therapeutics INC | — | NEW | New buy |
| 18 | TSHA | Taysha Gene Therapies INC | — | EXIT | Sold out |
| 19 | CTMX | Cytomx Therapeutics INC | — | NEW | New buy |
| 20 | CATX | Perspective Therapeutics INC | — | NEW | New buy |
| 21 | ALMS | Alumis INC | — | NEW | New buy |
| 22 | URGN | UroGen Pharma Ltd. | — | NEW | New buy |
| 23 | CAPR | Capricor Therapeutics INC | — | NEW | New buy |
| 24 | MAZE | Maze Therapeutics INC | — | NEW | New buy |
| 25 | IKT | Inhibikase Therapeutics INC | — | NEW | New buy |
| 26 | ANTX | An2 Therapeutics INC | — | NEW | New buy |
| 27 | RLMD | Relmada Therapeutics INC | — | NEW | New buy |
| 28 | KPTI | Karyopharm Therapeutics INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-18 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-14 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-15 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-16 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-14 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-15 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-16 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-17 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-16 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001782974
Total reported value
$123.8M
5 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0002095682
Total reported value
$123.8M
128 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0002066524
Total reported value
$123.8M
65 stks
2026-06-30
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0000938206
Total reported value
$13.6B
356 stks
2026-03-31
1 of the top 5 holdings overlap, including Praxis Precision Medicines I
CIK 0001009258
Total reported value
$8.5B
82 stks
2026-03-31
1 of the top 5 holdings overlap, including Praxis Precision Medicines I
CIK 0001081698
Total reported value
$358.8M
265 stks
2026-03-31
1 of the top 5 holdings overlap, including Compass Pathways PLC